TBPH · Company research
Theravance Biopharma, Inc. (TBPH): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
17records availableOther
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Theravance Biopharma Inc (NASDAQ: TBPH) Share Price, TBPH Stock News, TBPH Share Price & Updates - Kalkine | Theravance Biopharma Inc (NASDAQ: TBPH) Share Price, TBPH Stock News, TBPH Share Price & Updates Kalkine | View source ↗ | Kalkine | Oct 9, 2026 | neutral | 0 | 0.6 |
| Theravance Biopharma, Inc. SEC Filing (Oct 5, 2026) - Stock Titan | Theravance Biopharma, Inc. SEC Filing (Oct 5, 2026) Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| $17 a share in cash, plus rights to possible payments: a Theravance Biopharma (TBPH) director's shares convert. - Stock Titan | $17 a share in cash, plus rights to possible payments: a Theravance Biopharma (TBPH) director's shares convert. Stock Titan | View source ↗ | Stock Titan | Sep 24, 2026 | neutral | 0 | 0.6 |
| A 150,000-share insider option was cancelled without payment in Theravance Biopharma (TBPH)'s merger. - Stock Titan | A 150,000-share insider option was cancelled without payment in Theravance Biopharma (TBPH)'s merger. Stock Titan | View source ↗ | Stock Titan | Sep 24, 2026 | neutral | 0 | 0.6 |
| At $17 each, a director's shares in Theravance Biopharma (TBPH) were canceled, with a contingent right per share. - Stock Titan | At $17 each, a director's shares in Theravance Biopharma (TBPH) were canceled, with a contingent right per share. Stock Titan | View source ↗ | Stock Titan | Sep 24, 2026 | neutral | 0 | 0.6 |
| Theravance Biopharma CEO's 1.38M shares canceled | TBPH Insider Trading - Stock Titan | Theravance Biopharma CEO's 1.38M shares canceled | TBPH Insider Trading Stock Titan | View source ↗ | Stock Titan | Sep 24, 2026 | neutral | 0 | 0.6 |
| Theravance Biopharma (TBPH) Edges Lower to $17.02, Consolidating Between Key Levels - Ascending Triangle - https://www.dars.gov.et/ | Theravance Biopharma (TBPH) Edges Lower to $17.02, Consolidating Between Key Levels - Ascending Triangle https://www.dars.gov.et/ | View source ↗ | https://www.dars.gov.et/ | Sep 20, 2026 | neutral | 0 | 0.6 |
| TBPH: Theravance Biopharma Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits | TBPH: Theravance Biopharma Inc Latest Stock Price, Analysis, News and Trading Ideas Stocktwits | View source ↗ | Stocktwits | Sep 18, 2026 | neutral | 0 | 0.6 |
| Zymeworks' Theravance Deal Is A Breath Of Fresh Cash Flow (NASDAQ:ZYME) - Seeking Alpha | Zymeworks' Theravance Deal Is A Breath Of Fresh Cash Flow (NASDAQ:ZYME) Seeking Alpha | View source ↗ | Seeking Alpha | Sep 18, 2026 | neutral | 0 | 0.6 |
| Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance | Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue? Yahoo Finance | View source ↗ | Yahoo Finance | Sep 9, 2026 | neutral | 0 | 0.6 |
| TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks - TradingView | TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks TradingView | View source ↗ | TradingView | Aug 11, 2026 | neutral | 0 | 0.6 |
| Theravance Biopharma (TBPH) Holds Ground at $16.93 as Traders Weigh Range-Bound Move - OBV Trend Line - siam.in | Theravance Biopharma (TBPH) Holds Ground at $16.93 as Traders Weigh Range-Bound Move - OBV Trend Line siam.in | View source ↗ | siam.in | Aug 11, 2026 | neutral | 0 | 0.6 |
| Theravance Stock Down 3% After Zymeworks Announces Buyout - Yahoo Finance | Theravance Stock Down 3% After Zymeworks Announces Buyout Yahoo Finance | View source ↗ | Yahoo Finance | Jun 30, 2026 | neutral | 0 | 0.6 |
| Zymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH Shareholders - TradingView | Zymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH Shareholders TradingView | View source ↗ | TradingView | Jun 29, 2026 | neutral | 0 | 0.6 |
| Zymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH Shareholders - Stocktwits | Zymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH Shareholders Stocktwits | View source ↗ | Stocktwits | Jun 29, 2026 | neutral | 0 | 0.6 |
| TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates - PR Newswire | TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates PR Newswire | View source ↗ | PR Newswire | Apr 15, 2026 | neutral | 0 | 0.6 |
| TBPH Stock Slumps 30%, Falls Below 200-DMA For First Time In Over 9 Months As Phase 3 Study Misses Primary Endpoint - Stocktwits | TBPH Stock Slumps 30%, Falls Below 200-DMA For First Time In Over 9 Months As Phase 3 Study Misses Primary Endpoint Stocktwits | View source ↗ | Stocktwits | Mar 3, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.